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AbsTrACT
background and objective Dysferlinopathies are a 
group of muscle disorders caused by mutations in the 
DYSF gene. previous muscle imaging studies describe 
a selective pattern of muscle involvement in smaller 
patient cohorts, but a large imaging study across the 
entire spectrum of the dysferlinopathies had not been 
performed and previous imaging findings were not 
correlated with functional tests.
Methods We present cross-sectional T1-weighted 
muscle MRI data from 182 patients with genetically 
confirmed dysferlinopathies. We have analysed the 
pattern of muscles involved in the disease using 
hierarchical analysis and presented it as heatmaps. 
Results of the MRI scans have been correlated with 
relevant functional tests for each region of the body 
analysed.
results In 181 of the 182 patients scanned, we 
observed muscle pathology on T1-weighted images, with 
the gastrocnemius medialis and the soleus being the 
most commonly affected muscles. a similar pattern of 
involvement was identified in most patients regardless 
of their clinical presentation. Increased muscle pathology 
on MRI correlated positively with disease duration and 
functional impairment.
Conclusions The information generated by this study 
is of high diagnostic value and important for clinical 
trial development. We have been able to describe a 
pattern that can be considered as characteristic of 
dysferlinopathy. We have defined the natural history 
of the disease from a radiological point of view. These 
results enabled the identification of the most relevant 
regions of interest for quantitative MRI in longitudinal 
studies, such as clinical trials.
Clinical trial registration NcT01676077.
INTroduCTIoN
Dysferlinopathies are a group of autosomal reces-
sive muscular dystrophies caused by mutations in 
the DYSF gene.1 2 The absence or deficiency of 
dysferlin leads to muscle fibre necrosis and replace-
ment by fat and fibrous tissue. The two most 
frequent presentations are limb girdle muscular 
dystrophy type 2B (LGMD-2B) and distal myop-
athy with calf involvement or Miyoshi myopathy 
(MM).3 Other phenotypes, such as distal myopathy 
with anterior tibial involvement, proximodistal 
weakness and pseudometabolic presentation, have 
also been described.4 Clinical symptoms usually 
start in young adulthood and are associated with 
highly elevated serum creatine kinase levels. The 
disease progresses invariably producing muscle 
weakness that markedly impairs daily life activities. 
Respiratory and cardiac involvement is uncommon 
in patients with dysferlinopathy.5
In recent years, muscle MRI protocols have 
been developed to assess disease progression in 
muscular dystrophies using sequences that are 
able to quantify the amount of fat replacement per 
muscle.6 7 Previous muscle MRI studies in dysferl-
inopathy showed initial involvement of the adductor 
magnus, semimembranosus and vastus lateralis 
muscles in the thigh and gastrocnemius medialis, 
soleus and tibialis anterior in the legs. The pattern 
of muscle involvement has not been described to 
vary between phenotypes, although these findings 
were reported in small cohorts.8–11
Natural history studies are essential to understand 
the progressive course of muscular dystrophies and 
to identify suitable outcome measures that can be 
used in future clinical trials. To address this gap, 
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the Jain Foundation is funding The Clinical Outcome Study for 
Dysferlinopathy, a multicentre natural history study in a large 
cohort of patients (http://www. jain- foundation. org).12 Our aims 
in this paper are to identify the pattern of muscle pathology 
using MRI in a large cohort of patients with dysferlinopathy, to 
identify which muscles might be suitable to assess by quantitative 
MRI and study how MRI findings correlate with functional tests.
MeThods
study set-up and subjects
Two hundred and one patients with dysferlinopathy from 15 
sites (Newcastle, Barcelona, Seville, Munich, Berlin, Padua, 
Marseille, Paris, Saint Louis, Columbus, Charlotte, Washington 
DC, Stanford, Tokyo and Sydney) were enrolled in the study. 
One hundred and eighty-two patients had an MRI scan (clinical 
and genetic details are described in online supplementary file 
1). Inclusion criteria were ≥2 pathogenic mutations in DYSF or 
1 pathogenic mutation plus either absent dysferlin expression 
on skeletal muscle immunoblot or ≤20% blood dysferlin mono-
cyte expression. Truncating mutations and splice site mutations 
affecting the +1/–1 or +2/–2 positions were deemed patho-
genic. Pathogenicity of other splice site mutations and missense 
mutations was defined according to the UMD Predictor (http:// 
umd- predictor. eu).
Demographic data were collected for ethnicity, gender, age, 
ambulatory status and disease duration. Patients were strati-
fied according to the pattern of weakness at disease onset: (1) 
LGMD-2B, (2) MM, (3) proximodistal weakness, (4) other 
(pseudometabolic weakness). Those patients with no weakness 
at baseline examination but hyperCKemia were considered as (5) 
asymptomatic hyperCKemia. Disease duration was based on the 
time from onset of muscle weakness in symptomatic patients and 
time from first abnormal blood analysis result in patients with 
isolated hyperCKemia.
Functional status and physiotherapy assessment
Ambulation status was determined by the ability to walk 10 m 
with shoes and usual walking aids or orthotics. Physiotherapists 
assessed muscle strength in upper and lower limbs by manual 
muscle testing (MMT) using an Medical Research Council 
11-point scale (0=no movement, 1, 2, 3–, 3, 3+, 4–, 4, 4+, 
5–, 5=no weakness). A dysferlinopathy-adapted 22-item scale 
based on the original 17-item North Star Ambulatory Assess-
ment (NSAA) scale used in Duchenne muscular dystrophy and 
the Motor Function Measure were used to assess motor perfor-
mance.12 13 Timed tests (6 min walk test, rise from floor, 10 
m walk/run, time to climb and descend four steps and timed 
up and go tests) were performed in ambulant patients. The 
Brooke scale was performed to evaluate upper limb functional 
status and the ACTIVLIM as a patient-reported outcome 
measure.14 15
Muscle MrI: acquisition
One hundred and eighty-two patients underwent a baseline 
muscle MRI scan, of which 84 patients had whole body and 
98 patients lower limb scans. The core protocol consisted of 
T1-weighted, Dixon, B1 map and T2-weighted sequences. Here, 
we report the findings using anatomical T1-weighted sequences. 
The manufacturer, models and axial T1-weighted parameters are 
detailed in online supplementary file 2. The quality of the MRI 
studies was analysed by the study radiologists.
Muscle MrI: semiquantitative assessment
A blinded neurologist (RF-T) and radiologist (JL), both with 
experience in muscle MRI in neuromuscular disorders, inde-
pendently evaluated axial T1-weighted sequences with the semi-
quantitative Mercuri visual scale, modified by Fischer, described 
in online supplementary file 2.16 The observers agreed on the 
scoring of 96% of muscles. Inter-rater agreement kappa was 
0.93 (95% CI 0.91 to 0.96). For the remaining 4%, observers 
reviewed the muscles together and agreed a final score.
Genotype-MrI correlation
We divided the cohort into two groups depending on muta-
tion type: (1) patients in whom absent dysferlin expression was 
predicted (harbouring homozygous or compound heterozy-
gous truncating mutations) and (2) patients in whom reduced 
dysferlin expression was predicted (two missense mutations 
or one missense mutation and one truncating mutation). We 
compared median value of muscle fatty replacement between 
groups using the Wilcoxon-Mann-Whitney test.
statistics
We used the Shapiro-Wilk test to confirm that none of our 
variables were normally distributed. As such, non-parametric 
statistic tests were used for the analysis.
The Mann-Whitney U test was used to compare quantitative 
variables and the χ² test to compare qualitative variables. Due to 
the high number of comparisons studied, Bonferroni correction 
was used as posthoc analysis. To investigate correlations between 
muscle function tests and MRI findings, Spearman’s rank 
correlation was used (coefficient reported as ρ). The correlation 
was considered significant if p value was less than 0.05 and ρ was 
0.6 or higher. Hierarchical analysis and graphical representation 
as a heatmap was performed using R software, V.3.1.3. Statistical 
analyses were performed using IBM SPSS Statistics, V.21 (IBM, 
Armonk, New York, USA).
standard protocol approvals, registrations and patient 
consents
All participants provided informed consent. The study was 
approved by ethical review boards at each centre and registered 
at  ClinicalTrials. gov (NCT01676077).
resulTs
Patients
We included 182 patients (91 women, mean age at MRI 
38±12.6 years) from whom we have obtained muscle MRI 
scans. Demographic, clinical and genetic data are summarised in 
online supplementary file 3.
Muscle MrI involvement: general features
Signal abnormalities in T1-weighted images were detected in all 
but one patient (181 out of 182 patients). Asymmetric involve-
ment, judged as a score difference of at least 2 points in at least 
one muscle, was found in 77 patients (41.8%) although in 51/77 
patients the asymmetry was found in one muscle only. Asym-
metry in two or more muscles was found in 26/77 patients. 
Muscles that had asymmetric involvement were variable.
Cranial muscles
Cranial involvement was analysed in 73 patients and fatty replace-
ment was detected in 25 (34.2%). The tongue (34.2%) and 
the cervical paraspinal muscles (24.6%) were most commonly 
involved (figure 1A–D). In contrast, temporalis, masseter and 
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sternocleidomastoideus muscles were least commonly affected 
(only in 1, 2 and 3 patients, respectively). The degree of fat 
replacement of the cervical paraspinal and sternocleidomastoideus 
muscles had a statistically significant correlation with item 1 ‘lifts 
head from supine’, from the NSAA-a, although the correlation 
coefficient was poor (ρ=0.46) (table 1).
Figure 1 axial T1-weighted muscle MRI in dysferlinopathy. The cranial muscles (a–B) more commonly replaced by fat are the tongue (T) and the cervical 
paraspinal muscles (cps). Levator scapulae (Ls) is generally not involved until later stages of the disease (c, no involvement; D, involvement). In the scapular 
region (e–h) the subscapularis (sc) is involved at the early stages; other muscles such as deltoid (De), infraspinatus (Is) or supraspinatus (ss) become 
progressively involved. Rhomboideus (R) tends to be not involved until later stages of the disease (e–G, no involvement; h, involvement in an advanced 
case). Biceps brachii (Bi), triceps brachii (Tr) and the anterior muscles of the forearm (Fa) are commonly involved (I–K), while the posterior muscles of the 
forearm (Fp) are not involved even in later stages of the disease. Latissimus dorsi (LD) tends to be involved before serratus anterior (sa) in most of the 
patients (I–J). paraspinal muscles including the multifidus (M), the longissimus (L) and the iliocostalis (Ic) are affected in most of the patients at symptom 
onset, while abdominal muscles, such as rectus abdominis (Ra) are more resistant and become affected only in latter stages (K). Gluteus minor (GMi) is more 
severely involved than gluteus medius (GMe) and maximus (GMa) (L–M). pelvic floor muscles are transformed by fat in patients with dysferlinopathy, with 
the tensor fascia latae (TFL), obturatorius externus (Oe) and internus (OI) being the muscles more commonly involved (N–O). The posterior muscles of the 
thighs (semimembranosus (sm), biceps femoris long head (BLh), biceps femoris short head (Bsh) or adductor major (aM)) are commonly involved in most of 
the patients (p–s). Bsh tend to be less involved than BLh in early and mid-stage patients (Q). Vasti muscles are commonly involved even in early stages of 
the diseases (vastus intermedius (VI) in R). In contrast Sartorius (sa) and gracilis (Gr) are not involved until late stages of the disease (Q and s). analysis of 
the lower legs (T–W) shows initial involvement of gastrocnemius medialis (GM) and lateralis (GL) and soleus (so). Peroneus muscles (pe) are also involved in 
most of the patients (U). Later in the progression of the disease tibialis anterior (Ta) and posterior (Tp) become transformed by fat (V–W).
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Arm muscles
Arm involvement was analysed in 35 patients. Hierarchical 
analysis identified two more commonly and severely involved 
muscles (online supplementary figure 1A): the biceps brachii 
(57.1%) and the anterior muscles of the forearm (53.8%). 
Commonly observed patterns included:
1. The biceps brachii was equally or more severely involved 
than the triceps or the brachialis muscles (figure 1I,J, online 
supplementary figure 1 and table 2).
2. The anterior muscles of the forearm were equally or more 
severely involved than the posterior muscles of the forearm 
(figure 1K and online supplementary figure 1).
scapular muscles
Scapular involvement was analysed in 78 patients. Hierarchical 
analysis identified four muscles as more commonly and severely 
involved (figure 2): the subscapularis (80.8%), latissimus dorsi 
(75.3%), infraspinatus (73.8%) and supraspinatus (72.8%).
Commonly observed patterns included:
1. The subscapularis could be involved in patients even with-
out symptoms of proximal upper limb muscle dysfunction as 
measured by the Brooke or MMT (figure 1E and figure 2).
2. The supraspinatus and infraspinatus were equally or more 
severely involved than the rhomboideus (figure 1F–H and 
figure 2).
3. The latissimus dorsi was equally or more severely involved 
than the serratus anterior (figure 1I,J and figure 2).
4. If levator scapulae and rhomboideus were affected, subscapu-
laris, supraspinatus and infraspinatus were severely involved 
(Mercuri 3–4) (figure 1C–H and figure 2).
Trunk and pelvic muscles
Trunk and pelvic involvement was analysed in 89 patients. 
Hierarchical analysis identified six more commonly and more 
severely involved muscles (online supplementary figure 2): the 
tensor fascia latae (95%), gluteus minimus (90.8%), obturator 
externus (86%), iliocostalis (93.1%), longissimus (86.2%) and 
multifidus (88.5%).
Commonly observed patterns included:
1. Paraspinal muscles were equally or more involved than ab-
dominal muscles (figure 1J,K and online supplementary fig-
ure 2).
2. The gluteus minimus was more severely involved than glu-
teus medius and gluteus maximus (figure 1L,M and online 
supplementary figure 2).
3. The obturator externus was equally or more severely in-
volved than the gluteus maximus (figure 1L–O and online 
supplementary figure 2).
Table 1 Correlation found between muscle MRI scores and the 
appropriate muscle function test per every region of the body
body region Functional score
spearman 
test
Correlation 
coefficient
Cranial muscles NSAA item 1 (lift head) 0.0001 −0.46
Arm muscles Brooke score 0.0001 0.77
MMT biceps* 0.0001 −0.68
Scapular muscles Brooke scale 0.0001 0.68
ACTIVLIM scale 0.0001 −0.57
Trunk/pelvic 
muscles
NSAA item 12–13 (stand on one leg) 0.0001 −0.74
NSAA item 6 (get to sitting) 0.0001 −0.72
MMT glutei† 0.0001 −0.471
Thigh muscles Time to Climb 4 Steps 0.0001 0.63
Time to Up & Go 0.0001 0.63
ACTIVLIM Up Stairs 0.0001 0.53
ACTIVLIM Down Stairs 0.0001 0.68
MMT knee flexion‡ 0.0001 −0.63
Leg muscles NSAA item 20 (stand on heels) >0.05
NSAA item 28 (stand on tiptoes) >0.05
MMT plantar flexion§ >0.05
Trunk, pelvis, thigh 
muscles
6MWT 0.0001 −0.73
Time to run/walk 10 m 0.0001 0.55
*Correlation between the degree of muscle fatty transformation of the biceps brachii and 
the MMT of biceps.
†Correlation between mean degree muscle fatty transformation of the glutei muscles and 
MMT of hip extension.
‡Correlation between the mean degree of muscle fatty transformation of the posterior 
muscles of the thighs and MMT of knee flexion.
§Correlation between the mean degree of muscle fatty transformation of the posterior 
muscles of the lower legs and MMT of plantar flexion.
MMT, manual muscle test; MWT, minute walking test; NSAA, North Star Ambulatory 
Assessment.
Table 2 Percentage of patients for whom the every ‘pattern rule’ proposed was correct
Criteria % of cases
Biceps brachii equally or more severely involved than the triceps   100
Biceps brachii equally or more severely involved than brachialis 97.05
Anterior muscles of the forearm more severely involved than posterior muscles of the forearm 95.05
Patients in which subscapularis was involved despite not having symptoms of proximal upper limb muscle dysfunction as measured by the Brooke test and the manual 
muscle testing 
67.64
The supraspinatus was equally or more severely involved than the rhomboideus 97.01
The infraspinatus was equally or more severely involved than the rhomboideus 98.38
The latissimus dorsi was equally or more severely involved than the serratus anterior 95.55
If levator scapulae and rhomboideus were affected, subscapularis, supraspinatus and infraspinatus were severely involved 77.77
Paraspinal muscles were equally or more involved than abdominal muscles 95.4
Gluteus minimus equally or more severely involved than gluteus medius 98.86
Gluteus minimus equally or more severely involved than gluteus maximus 95.45
Obturator externus equally or more severely involved than the gluteus maximus 89.87
Biceps femoris long head equally or more involved than the biceps femoris short head 95.18
Adductor magnus equally or more severely involved than the adductor longus 80.98
Rectus femoris (Score1 to 4) was not spared when the vasti muscles were involved (Score 2, 3 or 4) 92.61
Sartorius and gracilis were not completely replaced by fat 92.22
All symptomatic patients had involvement of at least one posterior muscle in the lower legs   100
Peroneus equally or more involved than the tibialis anterior 91.57
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Thigh muscles
Thigh involvement was analysed in 182 patients. Hierarchical 
analysis identified four muscles that were more commonly 
and more severely involved (figure 3): the semimembranosus 
(95.4%), semitendinosus (90.2%), biceps femoris long head 
(93.5%) and adductor magnus (94.1%).
Commonly observed patterns included:
1. The biceps femoris long head was equally or more involved 
than the biceps femoris short head (figure 1P–S and figure 3).
2. The adductor magnus equally or more severely involved than 
the adductor longus (figure 1P–S and figure 3).
3. Rectus femoris was not spared when the vasti muscles were 
involved (Mercuri 2, 3 or 4) (figure 1P–S and figure 3).
4. The sartorius and gracilis were not involved until late stages, 
but even then were not commonly completely replaced by fat 
(figure 1P–S and figure 3).
lower leg muscles
Lower leg involvement was analysed in 182 patients. Hier-
archical analysis identified three more commonly and more 
severely involved muscles (figure 4C): the soleus (99.45%), 
gastrocnemius medialis (99.45%) and the gastrocnemius lateralis 
(94.7%).
Commonly observed patterns included:
1. All symptomatic patients had involvement of at least one pos-
terior muscle of the lower legs (figure 1T–W and figure 4).
2. Peroneus equally or more involved than the tibialis anterior 
(figure 1T–W and figure 4).
3. Patients with advanced disease could have involvement of all 
lower leg muscles, including the tibialis posterior (figure 1T–
W and figure 4).
Influence of demographic and clinical features on muscle 
involvement
There were gender differences in the degree of muscle fatty 
involvement in some muscles. The rectus abdominis, rectus 
femoris, vastus intermedius, vastus lateralis, vastus medialis, 
peroneus longus, peroneus brevis, gastrocnemius lateralis, 
gastrocnemius medialis and soleus were more severely involved 
Figure 2 heatmaps showing involvement of scapular muscles. patients and muscles are ordered according to hierarchical clustering with increasing 
grading in fat replacement severity from the bottom to the top (patients—rows) and from the left to the right (muscles—columns). The score of a muscle 
in a patient is indicated by the colour of the square. Grey squares mean that data are not available. The column in the top left contains information related 
to the phenotype of the patient at onset of the disease (legend in the bottom left). We have also included a column with information about the time from 
onset of symptoms to the MRI (years symptomatic) in blue and a column to the far right with the results of the Brooke and acTIVLIM scales (see legends for 
these scales at the bottom of the figure): the darker the square, the more time from onset (blue) or the worse the result of the Brooke (orange) or acTIVLIM 
scales. We found a statistically significant correlation between the median value of the Mercuri score per patient, the years symptomatic and the results of 
the Brooke and acTIVLIM scale. LGMD-2B, limb girdle muscular dystrophy type 2B. 
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in women (Mann Whitney U test, p<0.05). Ethnicity did not 
appear to influence the degree of involvement. Neither the 
type of mutation nor the phenotype at onset correlated with 
the pattern or severity of the fat replacement on MRI.
Influence of disease duration on the degree of muscle 
pathology: a natural history approach
Disease duration (defined here as time since onset of muscle 
weakness) correlated with the degree of fat replacement in all 
anatomical regions (Spearman’s test, p<0.0001). To investigate 
the sequence of muscle involvement as the disease progressed, 
we classified the patients into six groups depending on the 
time to MRI from onset and calculated the median value of fat 
replacement of muscle tissue. The heatmaps obtained revealed a 
pattern of disease progression (figure 5). The muscles involved 
in the earliest stages of the disease were predominantly in the 
lower limbs, pelvis or trunk, although the subscapularis and 
the latissimus dorsi could also be involved early (figure 5). The 
rate at which fatty replacement progressed varied between 
muscles, for example, the soleus, gastrocnemius medialis and 
semimembranosus were usually completely involved after 10 
years, while the adductor magnus or vastus lateralis were only 
completely involved when disease duration approached 25 
years.
Correlation between functional tests and the muscle Mercuri 
score
The degree of fatty replacement on semiquantitative muscle 
MRI was correlated with the Brooke scale for the upper limbs, 
the 6 min walking test (6MWT) for the lower limbs and the 
NSAA, MMT and timed tests (table 1).
For the scapular muscles, we classified the patients into five 
groups according to the Brooke scale (the two least able scores 
were grouped together and indicated by the number 5) and 
calculated the median value of fat per muscle in every group 
of patients. The heatmap obtained (online supplementary figure 
3) showed that the subscapularis, latissimus dorsi, infraspinatus 
and supraspinatus were involved in all patients, even if they were 
in the most functional group (ie, score of 1), while the levator 
scapulae or rhomboideus were only mildly involved, even in the 
least able patients (score 4 and 5).
For the lower limbs, we classified patients into groups 
depending on distance covered in the 6MWT and calculated 
the median value of fat replacement for each muscle (figure 6). 
Using this approach, we suggest which muscles would be 
useful to follow longitudinally with muscle MRI according to 
the result of the 6MWT. For example, in the case of patients 
walking 600–700 m, the soleus, gastrocnemius medialis and the 
peroneus group were already involved, though to a mild degree. 
In contrast, these four muscles were completely transformed 
in patients walking 300–400 m and would therefore not be 
Figure 3 heatmap of the muscle involvement of the thigh muscles. patients and muscles are ordered according to hierarchical clustering with increasing 
grading in severity of fat replacement from the bottom to the top (patients—rows) and from the left to the right (muscles—columns). The score of a muscle 
in a patient is indicated by the colour of the square. Grey squares means that data is not available. a column in the far left contains information related to 
the phenotype of the patient at onset of the disease (Yellow: LGMD-2B; red: Miyoshi). We have also included a column with information about the time from 
onset of symptoms to the MRI (years symptomatic) in blue and a column on the far right with the results of the Timed Up & Go and Time to climb 4 stairs 
tests in red: the darker the square the more time from onset (blue) or the worse the result of the Time to Up & Go (red). We found a statistically significant 
correlation between the median value of the Mercuri score per patient, the years symptomatic and the results of the time to Up & Go test. LGMD-2B, limb 
girdle muscular dystrophy type 2;  MMT, manual muscle testing. 
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suitable for follow-up once function has decreased to this level. 
At this point, the graphic shows that the tibialis anterior, vastus 
intermedius or even the vastus medialis would be more useful 
for follow-up. In non-ambulant patients, the muscles useful 
for follow-up included the gracilis, the gluteus medius or the 
piriformis.
dIsCussIoN
We have characterised muscle involvement on MRI in a large 
and clinically heterogeneous cohort of patients with dysferl-
inopathy. This large cross-sectional cohort has permitted better 
characterisation of the pattern of muscle involvement in dysfer-
linopathy and improved our understanding of disease progres-
sion. This information will support both diagnostics and clinical 
trial development.
We have defined a characteristic pattern of muscle involve-
ment for dysferlinopathy, independent of the clinical pheno-
type. An early combination of fat replacement in distal posterior 
muscles of the lower limbs (gastrocnemius medialis and soleus) 
together with involvement of posterior muscles of the thighs 
(semimembranosus, semitendinosus, adductor major), pelvic 
muscles (tensor fascia latae and obturator externus), paraspinal 
muscles (multifidus, iliocostalis) and the scapular muscles 
(subscapularis and latissimus dorsi) can be helpful for differen-
tial diagnosis of patients with a muscle dystrophy and lead to 
an early diagnosis of dysferlinopathy. Moreover, some muscles 
are not involved until very late in the disease such as the levator 
scapulae, the rhomboideus the posterior muscles of the forearms, 
the gluteus maximus and medius muscles and the gracilis. This 
pattern of muscle involvement and sparing could be helpful for 
differential diagnosis by MRI in severely affected patients, in 
whom obtaining a muscle biopsy may be challenging.
We confirmed that there are no differences in the pattern of 
muscle involvement between patients with LGMD-2B, MM 
or other phenotypic presentations.9–11 This suggests that these 
subtypes of dysferlinopathy are not truly different and that a 
unifying pathophysiology is likely, similar to findings in other 
muscle diseases, such as the laminopathies, where different muta-
tions result in similar patterns of selective muscle pathology.17 
Extensive MRI investigations, rather than clinical descriptions, 
are therefore more likely to be helpful in understanding the 
pathophysiology of disease or the role of genetic modifiers. As 
previously mentioned, some muscles were more involved in 
women than men. Although we do not have a clear explana-
tion to explain this issue, it is well known that testosterone and 
estrogens influence skeletal muscle homeostasis and metabolism 
Figure 4 heatmap of the muscle involvement of the lower leg muscles. patients and muscles are ordered according to hierarchical clustering with 
increasing grading in fat replacement severity from the bottom to the top (patients—rows) and from the left to the right (muscles—columns). The score of 
a muscle in a patient is indicated by the colour of the square. Grey squares means that data is not available. a column in the far left contains information 
related to the phenotype of the patient at onset of the disease (Yellow: LGMD-2B; red: Miyoshi). We have also included a column with information about 
the time from onset of symptoms to the MRI (years symptomatic) in blue. We found a statistically significant correlation between the median value of the 
Mercuri score per patient and the years symptomatic. LGMD-2B, limb girdle muscular dystrophy type 2B. 
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and probably have an effect on muscle wasting in muscle dystro-
phies.18 Exercise has been shown to be important for muscle size 
and metabolism, which may be a factor rather than gender here.
The pattern of muscle involvement reported here can be 
considered characteristic for dysferlinopathy and contributes to 
differential diagnosis between other muscle diseases with limb 
girdle weakness. Patients with Becker muscular dystrophy tend 
to have early fatty replacement of the glutei medius and maximus 
while in contrast the adductor longus tends to be preserved until 
later stages.18 19 Muscle MRI scans of patients with LGMD-1B 
show no involvement of the vasti until later stages although the 
rectus femoris tends not to be affected and is often hypertro-
phic.17 20 Patients with LGMD-2A tend to have more severe 
involvement of the glutei and the vasti are less involved than 
the posterior muscles of the thighs.21 22 This pattern is similar 
in patients with LGMD-2I.23 Patients with sarcoglycanopathy, 
Figure 5 heatmap showing the progression of the muscle involvement related to the time from onset of symptoms to the MRI. patients were divided 
into six groups for the analysis of the progression of muscle involvement. Muscles (columns) are ordered according to hierarchical clustering with increasing 
grading of muscle fatty replacement in T1-W imaging from the left to the right. The score of a muscle per every group is indicated by the colour of the 
square. We obtained a pattern of the progression of the disease related to the time from onset of symptoms to the MRI showing the natural history of the 
disease.
Figure 6 heatmap showing the progression of the muscle involvement related to the distance covered in the 6MWT. patients were divided into eight 
groups depending on the distance covered in the 6MWT for the analysis of the progression of muscle involvement. Muscles (columns) are ordered according 
to hierarchical clustering with increasing grading of muscle fatty transformation in T1-W imaging from the left to the right. The score of a muscle per group 
is indicated by the colour of the square. We obtained a pattern of the progression of the disease in muscles of the pelvis, thighs and lower legs related to the 
functional test 6MWT. 
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in whom there is usually no involvement of muscles of the 
lower legs before loss of ambulation, are easy to distinguish.24 
Patients with adult-onset Pompe, which presents frequently with 
limb girdle weakness, have a muscle MRI pattern characterised 
by early involvement of axial, abdominal, gluteal and posterior 
thigh muscles, with the muscles of the lower legs not commonly 
involved.25 26 Patients with mutation in ANO5 (LGMD-2L) have 
a similar pattern of muscle involvement compared with patients 
with dysferlinopathy, with predominant involvement of the 
posterior muscles of the lower legs associated with involvement 
of posterior and anterior muscles of the thighs without involve-
ment of the glutei.27–29 However, some differences can be found: 
the gluteus minimus and medius seem more commonly involved 
in LGMD-2L than in LGMD-2B and asymmetric involvement is 
more pronounced in LGMD-2L than dysferlinopathy.26 28
Previous similar radiological studies in dysferlinopathy 
have been performed in lower limbs only and involved small 
cohorts.9–11 30 Although these studies describe some of the 
features found here, we have expanded the range of patients 
analysed, using data from patients of different ethnic origins at 
many different stages of the disease.
We presented the pathology scores from T1-weighted images as 
heatmaps, as has been recently described for other muscle disor-
ders.31 32 This is a new approach to display large amount of data, 
which simplifies the analysis of several variables. Following this 
method, we identified a clear correlation between disease dura-
tion and the degree of muscle involvement. This analysis raises 
interesting questions about factors affecting the rate of muscle 
degeneration. We showed that some muscles were involved early, 
while others were not involved until much later. In addition, 
while a group of muscles could become involved at the same 
time, the progression of fat replacement between muscles in a 
group could also vary. For example, in most patients, the gastroc-
nemius medialis becomes completely replaced by fat in less than 
10 years from symptom onset, while the biceps femoris long 
head, while also involved in the first 10 years, remains minimally 
affected for longer. It is tempting to hypothesise that muscles 
with a slower progression could express proteins that protect 
them from rapid degeneration. Despite previous attempts to 
investigate this in dysferlinopathy, it is still not clear why muscle 
degeneration shows a different rate of progression.33 The clear 
understanding of the pattern of severely involved and spared 
muscles demonstrated here should allow for more focused inves-
tigations in the future.
T1-weighted muscle MRI has traditionally been used for 
differential diagnosis of muscle diseases or to select a suitable 
muscle to biopsy.34 35 As the development of novel therapeutics 
for many muscular dystrophies progresses, there is a growing 
need for reliable biomarkers to follow-up patients.36 We have 
shown that muscle MRI findings correlate with the results of most 
functional tests that may be included in clinical trials (table 1), 
adding weight to its use as a biomarker. However, as dysferlinop-
athy is a slowly progressive disorder, changes from 1 year to the 
next are probably not significant enough to be detectable using 
semiquantitative T1w imaging. Quantitative sequences such as 
3-point Dixon or T2-mapping should be more useful for patient 
follow-up in short-term longitudinal studies.37–39 However, the 
present study can inform longitudinal quantitative MRI studies 
regards which muscles to monitor at different stages of disease.
This work is the result of a large international collaboration 
between different clinical and radiological groups to harmonise 
MRI protocols. However, although the study includes a high 
number of patients with different phenotypes and different 
disease stages, it has some obvious limitations. First, not all 
patients were studied with whole body muscle MRI due to tech-
nical limitations in some centres. Second, the MRI systems used 
were different, which can include some variability in the data 
obtained. Third, there are no data regarding Short-TI Inversion 
Recovery  (STIR) results, but T2 imaging has been carried out 
and scans are currently under analysis.
In summary, our study provides information about the distri-
bution and degree of fat replacement of muscle tissue in the 
largest cohort of patients with dysferlinopathy analysed to date. 
The study has expanded the characterisation of patterns that can 
be found in patients with dysferlinopathy, regardless of their 
clinical phenotype. We have also shown a correlation between 
muscle pathology as detected by MRI with disease duration 
and the results of related functional tests, which will inform the 
design of future clinical trials.
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